Unusual Options Activity In United Airlines (UAL)
2579 $UAL APR 17th 2025 85.00 CALLS BOUGHT@ 8.1 vs Open Interest of 108 for a total of $2088990 on the BULL side
2579 $UAL APR 17th 2025 85.00 CALLS BOUGHT@ 8.1 vs Open Interest of 108 for a total of $2088990 on the BULL side
The Gap, Inc., commonly known as Gap Inc. or Gap, is an American worldwide clothing and accessories retailer. Gap was founded in 1969 by Donald Fisher and Doris F. Fisher and is headquartered in San Francisco, California. The company operates four primary divisions: Gap, Banana Republic, Old Navy, and Athleta.
Robinhood Markets, Inc. is an American financial services company headquartered in Menlo Park, California.
Crocs, Inc. engages in the design, development, manufacturing, worldwide marketing, sale, and distribution of casual footwear and accessories for men, women, and children. It operates through the following segments: North America, Asia Pacific, Europe, Middle East, Africa, and Latin America (EMEALA), and HEYDUDE Brand. The company was founded by Scott Seamans, George B. Boedecker, Jr., and Lyndon V. Hanson III in 2002 and is headquartered in Broomfield, CO.
BHP Group Limited (BHP) is a global resources company that mines, processes, and markets a variety of resources
Antero Resources Corporation is an American company engaged in hydrocarbon exploration. It is organized in Delaware and headquartered in Denver, Colorado.
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell diseases. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma; TG-1701 is an orally available and covalently-bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody.